Publicacións en colaboración con investigadores/as de Hospital Universitario de la Princesa (21)

2024

  1. Pegvisomant and pasireotide in PRL and GH co-secreting vs GH-secreting Pit-NETs

    Endocrine-Related Cancer, Vol. 31, Núm. 7

2023

  1. Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly

    Frontiers in Endocrinology, Vol. 14

2022

  1. Acromegaly disease activity according to ACRODAT®, a cross-sectional study in Spain: ACROVAL study

    Endocrine, Vol. 75, Núm. 2, pp. 525-536

2021

  1. Pasireotide in the Personalized Treatment of Acromegaly

    Frontiers in Endocrinology, Vol. 12

2020

  1. Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly

    Endocrine, Vol. 70, Núm. 3, pp. 575-583

2018

  1. Expert document on management of acromegaly

    Endocrinologia, Diabetes y Nutricion, Vol. 65, Núm. 8, pp. 428-437

2016

  1. Genetic Predictors of Response to Different Medical Therapies in Acromegaly

    Progress in Molecular Biology and Translational Science (Elsevier B.V.), pp. 85-114

  2. Long-term treatment with pegvisomant for acromegaly: A 10-year experience

    Clinical Endocrinology, Vol. 84, Núm. 4, pp. 540-550

  3. Safety of long-term treatment with Pegvisomant: analysis of Spanish patients included in global ACROSTUDY

    Pituitary, Vol. 19, Núm. 2, pp. 127-137

  4. Use of lanreotide in combination with cabergoline or pegvisomant in patients with acromegaly in the clinical practice: The ACROCOMB study

    Endocrinología y nutrición: órgano de la Sociedad Española de Endocrinología y Nutrición, Vol. 63, Núm. 8, pp. 397-408

2015

  1. Analysis of IGF(CA)19 and IGFBP3-202A/C gene polymorphisms in patients with acromegaly: Association with clinical presentation and response to treatments

    European Journal of Endocrinology, Vol. 172, Núm. 2, pp. 115-122

2014

  1. Cabergoline treatment in acromegaly: Pros

    Endocrine, Vol. 46, Núm. 2, pp. 215-219

2013

  1. Germline mutations of AIP gene in somatotropinomas resistant to somatostatin analogues

    European Journal of Endocrinology, Vol. 168, Núm. 1, pp. 9-13

  2. Pegvisomant and cabergoline combination therapy in acromegaly

    Pituitary, Vol. 16, Núm. 1, pp. 101-108

2011

  1. Lanreotide autogel-induced tumour shrinkage in thyrotropin-secreting pituitary macroadenomas

    Clinical Endocrinology

  2. Pituitary stalk dysgenesis-induced hypopituitarism in adult patients: Prevalence, evolution of hormone dysfunction and genetic analysis

    Neuroendocrinology, Vol. 93, Núm. 3, pp. 181-188

  3. Somatotroph tumor progression during pegvisomant therapy: A clinical and molecular study

    Journal of Clinical Endocrinology and Metabolism, Vol. 96, Núm. 2

2010

  1. Pegvisomant-induced liver injury is related to the UGT1A1*28 polymorphism of Gilbert's syndrome

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 5, pp. 2147-2154

  2. The exon 3-deleted growth hormone receptor is associated with better response to pegvisomant therapy in acromegaly

    Journal of Clinical Endocrinology and Metabolism, Vol. 95, Núm. 1, pp. 222-229

2009

  1. Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: Its efficacy in relation to gender and previous radio therapy

    European Journal of Endocrinology, Vol. 160, Núm. 4, pp. 535-542